Lymphocyte-rich classical Hodgkin lymphoma accounts for a small fraction of all Hodgkin lymphomas. Lymphocyte-rich classical Hodgkin lymphoma is a rare variant of classical Hodgkin lymphoma which resembles nodular lymphocyte predominance Hodgkin lymphoma, in terms of nodular growth and lymphocyte-richness, and mimics cHL, in terms of the immunophenotype of the tumour cells. Lymphocyte-rich classical Hodgkin lymphoma tumour cells have lost the B-cell phenotype, but express CD30 and the B-cell transcription program. As regards to genetics and cytogenetics findings please refer to the general features described in the CARDS related to nodular lymphocyte predominance Hodgkin lymphoma and classical Hodgkin lymphoma.
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Identity
Other names Nodular lymphocyte-rich classical Hodgkin lymphoma LRCHL Nodular lymphocyte-rich classical Hodgkin disease
Clinics and pathology

Disease
Hodgkin lymphoma (HL) has been classified into classical HL (cHL) , which accounts for 95% of all cases, and the less common nodular lymphocyte predominant HL (NLPHL) . A variant of cHL which resembles NLPHL, in terms of nodular growth and lymphocyte-richness, and mimics cHL, in terms of the immunophenotype of the tumour cells, was originally designated nodular lymphocyte-rich classic Hodgkin disease (Anagnostopoulos et al. 2000) , now called lymphocyte-rich cHL (LRCHL). LRCHL displays histologic and clinical features intermediate between those of cHL and NLPHL (Nam-Cha et al., 2009; Anagnostopoulos et al., 2008; Swerdlow et al., 2016) .
Phenotype/cell stem origin
Cell origin: LRCHL involves a clonal expansion of B lymphocytes which mimic those observed in the outer zone of germinal centers of lymphoid follicles (Nam-Cha et al., 2009 
Epidemiology
LRCHL accounts for only a small fraction (3% to 5%) of all HLs (Younes et al., 2014) , in similar frequency to NLPHL. The median age is similar to NLPHL and significantly higher than in other subtypes of cHL. There is a male predominance (Shimabukuro-Vornhagen, et al., 2005) .
Pathology
Among the four histological subtypes of cHL, nodular sclerosis and mixed cellularity are the most common subtypes, whereas the lymphocytedepleted and lymphocyte-rich subtypes are the less common 
Other features
Virology
At variance with NLPHL the neoplastic cells in LRCHL appear to be permissive for an EBV infection. EBV infection is observed in LRCHL tumour cells less frequently than in mixed cellularity cHL but more frequently than in nodular sclerosis cHL . (Younes et al., 2014) . Gloghini A and Carbone A. Atlas Genet Cytogenet Oncol Haematol. 2017; 21(1) It seems appropriate to mention here that the virologic characteristics of HL of the general population vary according to the immunocompetence status of the host and cHL subtype (IARC, 2012) as follows: cHL of the general population -Nodular sclerosis cHL, usually EBV negative -Mixed cellularity cHL, usually EBV positive -LRCHL, variably EBV positive -Lymphocyte depletion cHL, variably EBV positive -NLPHL usually EBV negative
Lymphocyte-rich classical Hodgkin lymphoma
Evolution
Clinically, patients with NLPHL and LRCHL show similar disease presentation but differ in the frequency of multiple relapses and prognosis after relapse. Patients with NLPHL and LRCHL differ from patients with cHL with nodular sclerosis or mixed cellularity, as they present with an earlier disease stage (Anagnostopoulos et al. 2000) .
Prognosis
Most LRCHLs have a better prognosis than do other cHLs.
Genetics
See the pertinent sections within the CARDS describing the general features of NLPHL and cHL (Küppers, 2011; Carbone and Gloghini, 2016; Gloghini and Carbone, 2016) .
